Overview

Copanlisib Plus Venetoclax in R/R DLBCL

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: - Copanlisib - Venetoclax
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AbbVie
Bayer
Treatments:
Venetoclax